Purpose: We quantified the underestimation of hospital readmission rates that can occur with institutional databases and the incidence of care fragmentation among patients undergoing urological oncology procedures in a nationally representative database. Materials and Methods: The 2013 Nationwide Readmissions Database was queried for patients undergoing prostatectomy, cystectomy, nephroureterectomy, nephrectomy, partial nephrectomy and retroperitoneal lymph node dissection for urological malignancies. Nationally representative 30 and 90-day readmission and care fragmentation rates were calculated for all procedures. Readmission rates with and without nonindex hospital readmissions were compared with Pearson's chi-square test. Multivariable logistic regression models were used to identify predictors of care fragmentation at 90-day followup. Results: For all surgical procedures readmission rates were consistently underestimated by 17% to 29% at 90-day followup. The rates of care fragmentation among readmitted patients were similar for all procedures, ranging from 24% to 34% at 90-day followup. Overall 1 in 4 readmitted patients would not be captured in institutional databases and 1 in 3 readmitted patients experienced care fragmentation. Multivariable models did not identify a predictor of care fragmentation that was consistent across all procedures. Conclusions: The high rate of underestimation of readmission rates across all urological oncology procedures highlights the importance of linking institutional and payer claims databases to provide more accurate estimates of perioperative outcomes and health care utilization. The high rate of care fragmentation across all procedures emphasizes the need for future efforts to understand the clinical relevance of care fragmentation in patients with urological malignancies, and to identify patients at risk along with potentially modifiable risk factors for care fragmentation.
POSTOPERATIVE readmission rates are an important quality metric that has been widely adopted by the urological community.
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0022-5347/17/1971-0235/0 THE JOURNAL OF UROLOGY rate. 3, 4 Researchers have recently started quantifying this problem by investigating the rate of nonindex hospital readmissions in patients undergoing major cancer surgeries. These studies have reported that 19% to 33% of readmitted patients are readmitted to a nonindex hospital. 5e8 Beyond nonindex hospital readmissions being problematic for accurately reporting readmission rates, they also lead to care fragmentation, which is associated with worse perioperative outcomes for surgical patients. 7e13 As a result, it is important for urologists to quantify the burden of care fragmentation experienced by their patients as it represents a target for quality improvement.
Therefore, the objectives of this study were 1) determine the incidence of nonindex hospital readmissions for patients undergoing major urological oncology surgeries in a nationally representative sample, 2) quantify the effect of excluding nonindex readmissions on reported readmission rates, and 3) quantify the rates of care fragmentation experienced by patients after urological oncology surgeries and identify predictors of care fragmentation.
METHODS

Data Source
The Nationwide Readmissions Database is drawn from the same sample of discharges as the Nationwide Inpatient Sample, linked to 21 State Inpatient Databases from the Healthcare Cost and Utilization Project, Agency for Healthcare Research and Quality.
14 The NRD was created with only data available for the 2013 calendar year, and it provides a unique opportunity to study hospital readmissions in a database that contains Medicare and nonMedicare beneficiaries. The NRD provides patient linkage and hospital ID numbers that can be used to track a patient across hospitals within a state. Moreover, the NRD is a stratified, single stage cluster sample of hospital discharges with weights that can be used to provide nationally representative estimates of readmission counts.
Patient Cohort
With institutional review board approval from the Johns Hopkins Medical Institutions, the 2013 NRD was queried using ICD-9 codes to identify patients who underwent cystectomy (57. 
Sociodemographic and Hospital Variables
Patient and hospital level exposure variables included age, gender, length of stay, primary payer, median household income national quartile for patient's home ZIP CodeÔ, hospital location, hospital bed size and patient disposition at discharge. A Charlson comorbidity index was calculated with a previously validated algorithm that uses ICD-9 diagnosis codes from the initial hospital discharge. 15 This was modified to exclude points due to cancer as all patients in this cohort had a cancer diagnosis. For each procedure the hospital procedure volume was determined to be low (50th percentile or less), intermediate (greater than 50th to 80th percentile) or high (greater than 80th percentile).
Surgical and Complication Variables
An open surgical approach was assumed for all procedures unless ICD-9 codes were present to indicate minimally invasive surgical approaches (54.21, 54.51, 17.4x). Complications during the initial hospitalization were identified using ICD-9 codes (supplementary table 1, http://jurology.com/). For patients treated with cystectomy ICD-9 codes were used to categorize the urinary diversion as an ileal conduit (56.51, 56.71), a continent diversion (57.87), ureterostomy (56.61) or unknown. 16 
Outcomes
Patients were identified as having a 30 or 90-day readmission if the duration from the initial hospitalization discharge to a subsequent admission was 30 days or less, or 90 days or less, respectively. These points were chosen because they are commonly reported in the urological oncology literature as outcome measures. 11, 17 Index readmissions were defined as readmissions for which the hospital ID number of the initial hospitalization discharge and readmission discharge were identical. Nonindex readmissions were defined as readmissions for which the hospital ID number of the initial hospitalization discharge and readmission discharge were different.
For each procedure the patients were stratified into 4 readmission groups based on pattern of readmission. The groups included patients who experienced 1) only an index hospital readmission, 2) only a nonindex hospital readmission, 3) an index and nonindex hospital readmission, and 4) no readmission during the followup period. This was done for 30 and 90-day followup durations. Patients with a transfer from a nonindex to an index hospital during readmission were classified as patients who experienced an index hospital readmission.
This approach was chosen because the Centers for Medicare & Medicaid Services consider transfers a single readmission.
Statistical Analysis
Sociodemographic, hospital and surgery characteristics were calculated for each procedure. For each oncologic procedure the 30 and 90-day readmission rates were calculated by combining the counts of all readmissions (readmission groups 1, 2 and 3).
To quantify the underestimation of readmissions that would occur if only index hospital readmissions were captured in a database, the proportion of 30 and 90-day readmitted patients (groups 1, 2 and 3) readmitted to only a nonindex hospital (group 2) was calculated for each procedure. Patients with index and nonindex hospital readmissions (group 3) were not included in the numerator of this calculation, as the index hospital database would capture a readmission for those patients. To compare whether the readmission rates were different with and without the underestimation, Pearson's chi-square was calculated comparing the 2 rates for the 30 and 90-day time frames.
To quantify the number of readmitted patients who experienced care fragmentation, the counts of the patients who had index and nonindex hospital readmission (group 3) and the only nonindex hospital readmission group (group 1) were combined, and divided by the total number of readmissions for a procedure (groups 1, 2 and 3).
Sociodemographic, hospital and surgery characteristics were calculated for each procedure, stratified by whether patients experienced care fragmentation during the 90-day followup period. Univariable and multivariable logistic regression models were used to determine predictors of care fragmentation during the 90-day followup period. These statistics were not calculated for RPLND due to the low absolute number of events in this group. For all analyses the appropriate weights were applied to take into account the stratified, single-stage cluster sample design of the NRD to yield nationally representative estimates. All analyses were conducted using StataÒ version 14. All reported p values were 2 sided and p 0.05 was considered statistically significant for all tests. 
RESULTS
With weighting
48,267 prostatectomies, 6,173 cystectomies, 3,371 nephroureterectomies, 18,541 nephrectomies, 12,135 partial nephrectomies and 382 RPLNDs met the study inclusion criteria. Sociodemographic, hospital and surgery characteristics for each procedure are shown in supplementary
Quantifying Underestimation
Across all surgical groups readmission rates were consistently underestimated by 17% to 29% at 90-day followup (see figure and table 1). At 30 and 90-day followup the rates of underestimation were 
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Proportion of 30-day (A) and 90-day (B) readmissions to index and nonindex hospitals by oncologic procedure. Blue area represents underestimation of readmission rates in conventional databases. Blue þ red area represents patients experiencing care fragmentation. similar among the procedures except for RPLND, which had much lower rates of underestimation at both points. The 30 and 90-day readmission rates with vs without underestimation are listed in table 2. For all procedures there was a significant difference between the 2 readmission rates at 30 and 90 days (all p <0.05).
Quantifying Care Fragmentation
Across all surgical groups the rates of care fragmentation among readmitted patients ranged from 24% to 34% at 90-day followup (see figure and table 1). At 30 and 90-day followup the rates of care fragmentation among readmitted patients were similar for the different procedures except RPLND at 30-day followup, which had a much lower rate of care fragmentation.
Predictors of Care Fragmentation
Multivariable models for predictors of care fragmentation at 90-day followup were evaluated with surgery (supplementary table 4 , http://jurology.com/). Of note, there were no variables that were predictors of care fragmentation across all surgeries.
DISCUSSION
To our knowledge this study provides the first nationally representative estimates of the rates of readmissions to index and nonindex hospitals for patients undergoing major urological oncologic surgeries, yielding the magnitude of underestimation of readmission rates that occurs in institutional databases and the rate of care fragmentation experienced by patients with urological cancer in the perioperative period. For all procedures the underestimation of readmission rates and the rate of care fragmentation were similar, highlighting the importance and large burden of these problems for all urological oncology procedures. The extent of underestimation of readmission rates was similar for all procedures, excluding RPLND, at 30-day (17% to 24%) and 90-day (23% to 29%) followup. At 30-day followup 1 of every 5 and at 90-day followup 1 of every 4 readmitted patients who underwent urological oncologic surgery would be missed by institutional databases that are unable to capture nonindex hospital readmissions. The readmission rates with vs without underestimation were significantly different for all procedures at 30 and 90-day followup. While the statistical significance of these difference is likely due to the large sample associated with nationally representative estimates, these results still highlight the need to link institutional databases containing clinical data to payer databases with claims data to better understand health care use and outcomes after discharge from the initial hospitalization. The ability of urological surgeons to accurately measure health care use is especially important given the transition from volume to value based purchasing. 18 Providers will be assuming increasing risk under the statutory mandates in the Medicare Access and CHIP Reauthorization Act of 2015, and these federal efforts will have a ripple effect across all payers. Therefore, for providers to develop and participate in payment models that accurately predict the risk of care use and spending will require an accurate assessment of readmission rates. Notably, the Centers for Medicare & Medicaid Services currently do not distinguish between readmissions at index or nonindex hospitals when measuring performance on readmission measures for the Hospital Readmission Reduction Program. 19 In this study at 90-day followup care fragmentation occurred in almost 1 of every 3 readmitted patients with urological cancer. Care fragmentation was the highest for readmitted patients treated with cystectomy (36.2% at 90-day followup), consistent with the findings of previous studies. 7, 11, 20 Therefore, patients treated with cystectomy represent a population of particular interest for future studies on the clinical implications of care fragmentation. However, the rates of care fragmentation were similar for all procedures except RPLND at 30-day followup, which indicates care fragmentation is equally problematic for all readmitted patients with urological cancer treated surgically. This is especially important in light of the current trends toward regionalization of urological oncology surgeries, which afford the benefit of having patients treated by high volume surgeons at high volume centers, but can expose patients to the harms associated with fragmentation of care as they travel farther for their initial surgery. 5,7e13,21,22 This effect of regionalization leading to increased care fragmentation is supported by our finding that high volume hospitals had a greater likelihood of care fragmentation than lower volume hospitals. Previous studies in surgical patient populations have demonstrated that care fragmentation is associated with higher rates of in-hospital mortality, subsequent readmissions, increased costs with readmission and higher rates of 1-year mortality.
7e13 However, it is important to realize there are certain instances in which nonindex readmissions may be preferred. For example, patients who travel long distances to undergo complex procedures at centers of excellence would likely prefer to be readmitted locally at nonindex institutions as long as outcomes are comparable.
We were unable to identify a predictor of care fragmentation that was consistent for all urological oncology procedures, highlighting that patients with urological cancer represent a diverse patient population with a different set of challenges for each procedure. Of note, high procedure volume, transfers to a facility and increased length of stay were associated with increased odds of care fragmentation in at least 1 procedure, and represent potentially modifiable risk factors. Moving forward, it will be important to identify potentially modifiable risk factors that predispose patients to experiencing care fragmentation. These actionable risk factors can then be modified through interventions to improve quality of care.
There are several limitations to this study. It was performed using an administrative database that does not contain pathological information about the cancers that were treated. However, we excluded patients with metastatic disease at initial hospital discharge as these patients are often excluded from studies investigating outcomes of surgical resection for urological cancer. Additionally, we excluded nonresidents of states in this study because the NRD only captures readmissions in a given state. As a result, our estimation of care fragmentation for these procedures is likely still an underestimation since nonresidents are more likely to experience readmission to a nonindex hospital located in the state in which they reside. In addition, the NRD does not contain variables related to regional variation, patient travel distance to hospital, surgeon volume or National Cancer Institute cancer center designation. These are important factors that future studies on care fragmentation should investigate. We were also unable to investigate the number of emergency department encounters that did not result in readmissions, which further highlights the need to merge claims data with clinical outcomes data. Moreover, we did not look at the outcomes of patients during hospital readmission or causes of readmissions as these were outside of the aims of this study.
CONCLUSIONS
Of every 4 readmitted patients treated with urological oncology surgery 1 will be readmitted to a nonindex hospital, while 1 in every 3 will experience care fragmentation. These findings highlight the need for databases that merge payer claims data with clinical information and the importance of improving urological oncology quality in relation to care fragmentation. Future research should focus on increasing our understanding of the clinical relevance and policy implications of care fragmentation as it represents an important quality of care metric that has not yet been evaluated for these urological oncology procedures, despite the fact that many patients with urological cancer treated surgically experience care fragmentation.
